Universal CAR-T Cells Targeting Multiple Myeloma
ConditionMultiple Myeloma in Remission
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorShenzhen Geno-Immune Medical Institute
About this trial
The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.
Eligibility criteria
Qualifiers
Patients with confirmed multiple myeloma failed curative treatment options (including autologous or allogeneic SCT).
Complete remission (CR) cannot be achieved after at least 2 prior therapy regimens.
High risk MM in CR1 or CR2 and not eligible for SCT because of age or comorbid diseases.
Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval < 1 year).
Disqualifiers
Pregnant or lactating women
Uncontrolled active infection
Active hepatitis B or hepatitis C infection
Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
Trial design
Treatments tested in this trial
- MM-specific universal CAR T cells
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov